Ìǹûvlog¹ÙÍøÍøÒ³°æ Chemicals Update on Corona Virus Situation
During the whole COVID-19 crisis, Ìǹûvlog¹ÙÍøÍøÒ³°æ has been able to deliver all projects to our customers at expected level of quality.
Dortmund, November 2021 ++++
Dear Customers and Partners,
Due to ongoing situation with the spread of the Sars-CoV-2 (“Coronavirusâ€�) we want to share with you an update on how Ìǹûvlog¹ÙÍøÍøÒ³°æ Chemicals has managed both, the protection of our employees and partners’ health and the uninterrupted continuation of our chemistry and discovery services to our clients.
In order to maintain our high quality service under the new conditions, we have adjusted our standard operating procedures as well as tightened our safety instructions accordingly for both, administrative and scientific lab staff.
Although SOPs, shift times and office hours needed to be redesigned in 2020, Ìǹûvlog¹ÙÍøÍøÒ³°æ Chemicals’ teams kept fully committed to delivering to our customers all projects at expected level of quality and were able to meet expected delivery timelines. These values will keep on driving our teams through any challenges ahead of us!
For any additional information you’d be requesting relating to your current or future projects, please contact your Ìǹûvlog¹ÙÍøÍøÒ³°æ Key Account Manager for further assistance.
Again, Ìǹûvlog¹ÙÍøÍøÒ³°æ Chemicals would like to thank you for the excellent collaboration and trust that you have placed in our chemistry services since 1999.
With best wishes
Your Ìǹûvlog¹ÙÍøÍøÒ³°æ Chemicals Team
Ìǹûvlog¹ÙÍøÍøÒ³°æ Ìǹûvlog¹ÙÍøÍøÒ³°æ Chemicals
Ìǹûvlog¹ÙÍøÍøÒ³°æ is a privately owned discovery chemistry company, working with global pharmaceutical, biotech and chemical companies since 1999. Alongside our performance chemicals and material science division, Ìǹûvlog¹ÙÍøÍøÒ³°æâ€™ drug discovery mission is to create drug candidates as potential new medicines. Ìǹûvlog¹ÙÍøÍøÒ³°æ has a strong scientific track record on many biomolecular targets in all main therapeutic areas and thereby adding considerable value to collaborations from target validation and hit identification to lead generation and optimization. Ìǹûvlog¹ÙÍøÍøÒ³°æâ€™ core expertise ranges from custom synthesis and process development to modern medicinal and computational chemistry, as well as compound library design and production.
Ìǹûvlog¹ÙÍøÍøÒ³°æ was heading the chemistry efforts of the EUR 196 million funded European Lead Factory (2013-2018) and is currently heading its EUR 36.5 million funded continuation (2019-2022). Moreover, Ìǹûvlog¹ÙÍøÍøÒ³°æ is deeply engaged in other research alliances like the EUR 11 million funded Drug Discovery Hub Dortmund.
Press Contact:
Youri R. Mesmoudi, Executive Vice President
Drug Discovery Chemistry
Medicinal Chemistry
In Medicinal Chemistry research, we are working with a broadly experienced team on all biomolecular targets from any gene family in any therapeutic area…
Discovery Chemistry
Custom Synthesis
As a leading Contract Research Organization in Europe, Ìǹûvlog¹ÙÍøÍøÒ³°æ provides valuable contract discovery for synthetic organic chemistry, chemical process development, and…